PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
34.62%
G&A growth 50-75% of AVXL's 53.07%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
14.45%
Operating expenses growth 50-75% of AVXL's 20.54%. Bruce Berkowitz would examine efficiency.
14.45%
Total costs growth 50-75% of AVXL's 20.54%. Bruce Berkowitz would examine efficiency.
561.32%
Interest expense change of 561.32% while AVXL maintains costs. Bruce Berkowitz would investigate control.
-26.41%
D&A reduction while AVXL shows 29.69% growth. Joel Greenblatt would examine efficiency.
55.40%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth above 1.5x AVXL's 99.82%. Michael Burry would check for concerning trends.
43.33%
Pre-tax income growth below 50% of AVXL's 91.89%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense growth 50-75% of AVXL's 809.11%. Bruce Berkowitz would examine efficiency.
43.33%
Net income growth below 50% of AVXL's 91.89%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth below 50% of AVXL's 91.88%. Michael Burry would check for structural issues.
43.35%
Diluted EPS growth below 50% of AVXL's 91.88%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.